Hospitals spent $83 billion in 2008 caring for people with diabetes with one out of every five hospitalizations being a person that has diabetes. This was according to a report prepared by the Healthcare Research and Quality Agency (AHRQ)…

Consumers’ growing demand for nutritional guidance spurred the creation of NuVal. NuVal’s labeling system evaluates foods based upon more than 30 nutritional attributes, including positive ones such as fiber and negative ones such as saturated fat. It uses a mathematical formula to assign products a score on a scale of …

Our patients often use the internet to learn more about the conditions we diagnose and the medications and procedures we use to treat them. Often they come to us with good information and seem to have become “specialists” at their own condition. At times this can make it easier for …

by Isaak Smith, PharmD Candidate, University of Florida College of Pharmacy Contrave (naltrexone SR/bupropion SR) is an investigational product from Orexigen, a company that specializes in the treatment of obesity. Contrave has just completed phase-3 trials (COR-1, COR-2, COR-BMOD, and COR-diabetes) and Orexigen has submitted an NDA to the FDA …

DJ: What is the anticipated timeline for commercialization if all goes well?

DJ: Will there be any application of this drug class for Type 2 diabetes?

DJ: What kind of results have you seen so far?

DJ: What distinguishes otelixizumab from other drugs in its class?  

DJ:  What are the tradeoffs?  

DJ: How does the (anti-CD3 monoclonal antibody) drug class function?